Ongoing shortage of GLP-1 drugs Exploding demand and off-label use (for yet to be approved indications such as type-1 diabetes) are causing a supply shortage for GLP-1 agonists, which is likely to prevail in the near-term
Incretin analogues also show beneficial effects in heart failure, peripheral vascular disease, renal disease, obstructive sleep apnoea and metabolic dysfunction-associated steatohepatitis and have potential neuroprotective properties
Drug-metabolizing enzyme- and transporter-mediated DDIs involving GLP-1 RAs and a dual GLP-1/GIP RA require careful evaluation
Tesamorelin has also been linked to glucose intolerance and a higher risk of type 2 diabetes, and is contraindicated in pregnancy
Energy fades slowly
Wang R, Xue G, Hlscher C, Tian M, Feng P